CRISPR Therapeutics

News

ICER backs sickle cell gene therapies at one-off cost of $2m

The influential Institute for Clinical and Economic Review (ICER) in the US has issued draft guidance suggesting that new gene therapies for sickle cell disease (SCD) from

News

Vertex/CRISPR file first gene-editing therapy with FDA

Vertex Pharma and CRISPR Therapeutics have become the first companies to file for FDA approval of a therapy based on gene-editing technology.

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Vertex, CRISPR prep filing for gene-editing blood disorder t...

Vertex Pharma and partner CRISPR Therapeutics will start a rolling marketing application in the US for their gene-editing drug for sickle cell disease (SCD) and beta thalassaemia later this

News

EHA: Vertex, CRISPR build case for gene-editing drug

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update at the EHA congress showing long-term effec

News